ストックスクリーナーアプリを入手
8.95
0.22%
0.02
アフターアワーズ：
8.85
-0.10
-1.12%
前日終値:
$8.93
開ける：
$8.95
24時間の取引高:
765.49K
Relative Volume:
0.64
時価総額：
$502.41M
収益：
$27.46M
当期純損益:
$-46.05M
株価収益率:
-6.938
EPS:
-1.29
ネットキャッシュフロー:
$-33.83M
1週間 パフォーマンス:
-1.32%
1か月 パフォーマンス:
-21.77%
6か月 パフォーマンス:
+16.23%
1年 パフォーマンス:
+23.79%
1日の値動き範囲:
$8.72
$8.99
1週間の範囲:
$8.645
$9.35
52週間の値動き範囲:
$6.19
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
名前
Zevra Therapeutics Inc
セクター
電話
(321) 939-3416
住所
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
ZVRA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
8.95 | 501.29M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-02 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-08 | 再開されました | Cantor Fitzgerald | Overweight |
| 2024-10-07 | 開始されました | Guggenheim | Buy |
| 2024-09-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-09-24 | 繰り返されました | Maxim Group | Buy |
| 2024-04-02 | 繰り返されました | Maxim Group | Buy |
| 2024-03-12 | 開始されました | William Blair | Outperform |
| 2023-03-17 | 開始されました | Maxim Group | Buy |
すべてを表示
Zevra Therapeutics Inc (ZVRA) 最新ニュース
Is Zevra Therapeutics Inc. stock a good dividend stockWeekly Trading Summary & Technical Pattern Alert System - خودرو بانک
Is Zevra Therapeutics Inc. a strong growth stockWeekly Trade Report & Low Drawdown Momentum Trade Ideas - خودرو بانک
What’s the recovery path for long term holders of Zevra Therapeutics Inc.Market Activity Recap & Free Community Consensus Stock Picks - Newser
Is Zevra Therapeutics Inc. a good ESG investmentGap Down & Free Verified High Yield Trade Plans - خودرو بانک
What analysts say about Zevra Therapeutics Inc. stockWeekly Profit Report & High Return Trade Opportunity Guides - خودرو بانک
Quantitative breakdown of Zevra Therapeutics Inc. recent moveQuarterly Investment Review & Long-Term Safe Return Strategies - Newser
Measuring Zevra Therapeutics Inc.’s beta against major indicesMarket Weekly Review & Precise Swing Trade Alerts - Newser
Using Python tools to backtest Zevra Therapeutics Inc. strategiesMarket Performance Summary & Advanced Technical Analysis Signals - Newser
Zevra Therapeutics Inc. stock retracement – recovery analysisSell Signal & Safe Entry Momentum Tips - Newser
Using data models to predict Zevra Therapeutics Inc. stock movementStock Surge & Free Technical Confirmation Trade Alerts - Newser
Does Zevra Therapeutics Inc. qualify in momentum factor screeningWeekly Profit Report & Expert Curated Trade Setup Alerts - Newser
Volume spikes in Zevra Therapeutics Inc. stock – what they meanTrade Risk Report & Safe Entry Trade Signal Reports - Newser
What recovery options are there for Zevra Therapeutics Inc.July 2025 Market Mood & Reliable Entry Point Alerts - Newser
Zevra Therapeutics Presents Positive New Data Supporting - GlobeNewswire
Disease Progression Slowed: Zevra's MIPLYFFA Shows Breakthrough Results in Rare Niemann-Pick Disease Trial - Stock Titan
How does Zevra Therapeutics Inc. compare to its peersMarket Sentiment Review & AI Driven Stock Price Forecasts - خودرو بانک
What makes Zevra Therapeutics Inc. stock price move sharplyJuly 2025 Review & Expert Approved Momentum Ideas - Newser
Tools to monitor Zevra Therapeutics Inc. recovery probabilityEarnings Growth Report & High Return Stock Watch Alerts - Newser
Can you recover from losses in Zevra Therapeutics Inc.Weekly Market Report & Low Drawdown Momentum Ideas - Newser
Fund Flows: What is Zevra Therapeutics Inc.’s market positionProfit Target & Fast Momentum Stock Entry Tips - خودرو بانک
Zevra Therapeutics at Cantor Conference: Rare Disease Strategy Unveiled - Investing.com
Does Zevra Therapeutics Inc. meet Warren Buffett’s criteria2025 Market Overview & Weekly Chart Analysis and Trade Guides - خودرو بانک
Predicting Zevra Therapeutics Inc. trend using moving averages2025 Growth vs Value & AI Enhanced Trading Signals - Newser
Zevra Therapeutics Inc. stock chart pattern explained2025 Retail Activity & Verified Entry Point Signals - Newser
How to manage a losing position in Zevra Therapeutics Inc.2025 Winners & Losers & Fast Exit and Entry Strategy Plans - Newser
Can Zevra Therapeutics Inc. recover in the next quarterChart Signals & Community Trade Idea Sharing Platform - Newser
Relative strength of Zevra Therapeutics Inc. in sector analysisTrade Risk Summary & Comprehensive Market Scan Insights - Newser
Is Zevra Therapeutics Inc. still worth holding after the dipJuly 2025 Decliners & Smart Investment Allocation Insights - Newser
Full technical analysis of Zevra Therapeutics Inc. stock2025 Key Highlights & Reliable Price Breakout Signals - Newser
Advanced analytics toolkit walkthrough for Zevra Therapeutics Inc.Jobs Report & Growth Oriented Trading Recommendations - Newser
How to build a dashboard for Zevra Therapeutics Inc. stockWeekly Stock Report & Short-Term High Return Ideas - Newser
Zevra Therapeutics gains amid takeover speculation - MSN
Is now a turning point for Zevra Therapeutics Inc.Market Risk Summary & Free Low Drawdown Momentum Trade Ideas - Newser
Is Zevra Therapeutics Inc. stock overhyped or has real potentialMarket Activity Summary & Real-Time Stock Price Movement Reports - Newser
Custom strategy builders for tracking Zevra Therapeutics Inc.2025 Buyback Activity & Fast Gain Stock Trading Tips - Newser
Is Zevra Therapeutics Inc. stock bottoming outJuly 2025 Decliners & AI Optimized Trading Strategy Guides - Newser
Real time scanner hits for Zevra Therapeutics Inc. explainedQuarterly Growth Report & Capital Efficient Trade Techniques - Newser
Zevra Therapeutics Inc (ZVRA) 財務データ
収益
当期純利益
現金流量
EPS
1.40%
大文字化:
|
ボリューム (24 時間):